TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer

John MacKey, Karen Gelmon, Miguel Martin, Nicole McCarthy, Tamas Pinter, Mathieu Rupin, Hagop Youssoufian

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

In this multinational, placebo-controlled, randomized phase III trial, Translational Research In Oncology (TRIO) will define the efficacy and safety of adding a novel antiangiogenic agent, IMC-1121B (ramucirumab), to standard first-line docetaxel chemotherapy for women with HER2-negative metastatic breast cancer. We will evaluate whether the addition of IMC-1121B prolongs progression-free survival and whether its use improves overall survival. Accrual is under way.

Original languageEnglish
Pages (from-to)258-261
Number of pages4
JournalClinical Breast Cancer
Volume9
Issue number4
DOIs
Publication statusPublished - Jan 1 2009

Keywords

  • Angiogenesis inhibitor
  • Bevacizumab
  • Ramucirumab
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'TRIO-012: A multicenter, multinational, randomized, double-blind phase iii study of imc-1121b plus docetaxel versus placebo plus docetaxel in previously untreated patients with her2-negative, unresectable, locally recurrent or metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this